In the setting of castrate-resistant prostate cancer, patients present with a variety of symptoms, including bone metastases, spinal cord compression and advanced pelvic disease. Fortunately, a variety of radiotherapeutic options exist for palliation. This article focuses on these options, including both external beam radiotherapy and radiopharmaceuticals.
Keywords: bone metastases; hemi-body radiotherapy; palliative radiotherapy; prostate cancer; radiopharmaceuticals; radium 223.